Email ID
Password
Scrip   
Poniard plunges after picoplatin fails pivotal lung cancer trial
17 November 2009
Malini Guha

Poniard Pharmaceuticals' only drug candidate in clinical development, the chemotherapeutic agent picoplatin, has failed to improve overall survival in its pivotal Phase III SPEAR trial in the second-line treatment of small cell lung cancer (SCLC), leading its shares to plunge by over 75% on Nasdaq...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36